Genetic Technologies Ltd has released a press release.
Form F-1 Prospectus SEC Filing
Filed with ASX ·
6ix hasn’t read this filing yet.
Genetic Technologies Limited on 6ix
Earlier from Genetic Technologies
- Genetype for Breast Cancer commissioned-Sales start Q1 2020
- Response to Appendix 3Y Query
- Non-Renounceable Rights Issue
- Director Resignation
- Collaboration Agreement signed between GTG and TGen
Later from Genetic Technologies
- Updated Form F-1 Prospectus SEC Filing
- Breast Cancer Test US Sales Update
- Half Yearly Report and Accounts
- Receipt of Delisting Notification Letter from Nasdaq
- USA Form F3 Registration Statement Lodged with SEC
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies